Benzinga | Aug 17, 2021 04:36AM EDT

SVB Leerink Maintains Outperform on Travere Therapeutics, Raises Price Target to $37

SVB Leerink analyst Joseph Schwartz maintains Travere Therapeutics (NASDAQ:TVTX) with a Outperform and raises the price target from $27 to $37.